Cohance Lifesciences receives warning letter for its Nacharam formulation facility
(04 Feb 2026)

Back
Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company's Nacharam formulation facility.

The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same.

The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025.

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew